Glenmark Pharmaceuticals Announces Entry into Branded Dermatology Segment in the United States

Glenmark Pharmaceuticals receives ANDA approval for Fluocinolone Acetonide Oil, 0.01% (Ear Drops)

Glenmark Pharmaceuticals Announces New Data on GBR 1302, a HER2xCD3 Bispecific Antibody, Presented at the ESMO Immuno-Oncology Congress 2018

Glenmark Pharmaceuticals receives ANDA approval for Hydrocortisone Valerate Ointment USP, 0.2%

Glenmark Pharmaceuticals receives tentative ANDA approval for Clobetasol Propionate Foam, 0.05% (Emulsion Formulation)

Glenmark Pharmaceuticals receives ANDA approval for Atovaquone Oral Suspension USP, 750 mg/5 mL

Glenmark Pharmaceuticals receives ANDA approval for Azelaic Acid Gel, 15%

Glenmark Pharmaceuticals Announces New Data Presentations on Ryaltris™ at the ACAAI Annual Scientific Meeting 2018

Glenmark receives ANDA approval for Teriflunomide Tablets 7 mg and 14 mg

Glenmark’s consolidated revenue rises 14.39% to Rs. 25,813.32 Mn. in Q2 FY 2018 – 19

Glenmark Pharmaceuticals Announces Decision to Launch Phase 1 Trial in Solid Tumors for its CD38xCD3 Bispecific Antibody GBR 1342 Based on Human Translational Data

Glenmark launches globally-renowned hair growth formula Nourkrin® in Russia

Glenmark Pharmaceuticals receives ANDA approval for Fluocinolone Acetonide Topical Oil, 0.01% (Scalp Oil)

Glenmark Pharmaceuticals receives ANDA approval for Fluocinolone Acetonide Topical Oil, 0.01% (Body Oil)

Data on Glenmark’s GBR 830, First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody in Development for Treatment of Atopic Dermatitis, to be Presented at the Fall Clinical Dermatology Conference

Glenmark Pharmaceuticals receives ANDA approval for Hydrocortisone Valerate Cream USP, 0.2%

Glenmark Pharmaceuticals inducted into the Dow Jones Sustainability Indices (DJSI) Emerging Markets 2018, one of the most prestigious global sustainability benchmarks

Glenmark Pharmaceuticals receives ANDA approval for Estradiol Vaginal Inserts USP, 10 mcg

Glenmark secures marketing authorization in Germany for its generic version of Seretide® Accuhaler®

Glenmark enters into an exclusive licensing agreement to commercialize generic Tiotropium Bromide dry powder inhaler in Western Europe

Glenmark enters into a collaboration with True North for its orthopaedic and pain management business in India

Glenmark’s consolidated revenue at Rs. 21,656.17 Mn. for Q1 FY 2018 – 19

Glenmark Pharmaceuticals Announces FDA Acceptance of the Company’s First New Drug Application for Ryaltris™ for Patients with Seasonal Allergic Rhinitis

Glenmark Pharmaceuticals’ partner Elite Pharmaceuticals receives US FDA approval for generic methadone hydrochloride tablets

Glenmark Pharmaceuticals and Harbour BioMed Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers

Glenmark Pharmaceuticals Announces Encouraging Phase 1 Results Supporting Biosimilarity Criteria for GBR 310 Compared to the Reference Product Omalizumab

Glenmark Pharmaceuticals receives ANDA approval for Colesevelam Hydrochloride for Oral Suspension, 1.875 grams/Packet and 3.75 grams/Packet

Glenmark Pharmaceuticals expands its oncology franchise in India with the launch of Helsinn’s AKYNZEO®, a combination drug for the prevention of CINV (chemotherapy-induced nausea and vomiting)

Glenmark Announces Exclusive Licensing Agreement with Seqirus for its Investigational Seasonal Allergic Rhinitis Nasal Spray – Ryaltris – for Australia and New Zealand Markets

The US FDA Approves First Supplemental Abbreviated New Drug Application (sANDA) for Glenmark Pharmaceuticals’ Manufacturing Facility in Monroe, North Carolina